Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Adam Lister(University of Liverpool), B. Kevin Park(University of Liverpool), Bryony H. Lloyd(University of Liverpool), Taoufik Nedjadi(National Guard Health Affairs), Samantha Williams(University of Liverpool), Ian M. Copple(University of Liverpool), John P. Neoptolemos(University of Liverpool), Andrew Owen(University of Liverpool), Fiona Campbell(University of Birmingham), Eithne Costello(University of Liverpool), Neil R. Kitteringham(University of Liverpool), Christopher E. Goldring(University of Liverpool)
Cited by 240
Related Papers
What is meant by intention to treat analysis? Survey of published randomised controlled trials
|BMJ|1999|2.2k
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Effectiveness of brief alcohol interventions in primary care populations
|Cochrane Database of Systematic Reviews|2018|1.7k